Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing HBsAg Clearance in CHB Patients With Sequential Treatment of Pegylated Interferon Alpha-2b and Nucleoside Analogues
NCT02605252Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Mar 2016
- Primary completion
- Sep 2017
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Open-label, single-arm trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Hepatitis B surface antigen loss at Week 48. Status: unknown.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02605252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605252.